Biogen to make case to skeptics for its controversial Alzheimer's drug

Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news